15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $50M | -$50M | 99.4% | -98.2% | -$68M | $54M | $34M |
| 2024 | $31M | -$200M | 98.0% | -634.2% | -$180M | $100M | $67M |
| 2023 | $1M | -$177M | 92.9% | -14265.0% | -$162M | $100M | $22M |
| 2022 | $139000 | -$102M | 100.0% | -72489.2% | -$90M | $49M | $46M |
| 2021 | $298000 | -$88M | 100.0% | -29224.8% | -$88M | $0 | $64M |
| 2020 | $24M | -$59M | 92.0% | -199.2% | -$143M | $12M | $126M |
| 2019 | $322M | $130M | 99.0% | 43.9% | $114M | $249M | $36M |
| 2018 | $63M | -$121M | 96.1% | -163.4% | -$149M | $250M | $80M |
| 2017 | $92M | -$123M | 97.9% | -142.5% | -$186M | $252M | $62M |
| 2016 | $79M | -$131M | 100.0% | -160.5% | -$176M | $101M | $47M |
| 2015 | $130M | -$5M | 0.0% | 1.1% | $184M | $106M | $203M |
| 2014 | $23M | -$100M | 0.0% | -439.2% | -$76M | $108M | $137M |
| 2013 | $2M | -$104M | 0.0% | -4607.2% | -$93M | $22M | $37M |
| 2012 | $1M | -$110M | 0.0% | -9955.5% | -$95M | $23M | $30M |
| 2011 | $2M | -$116M | 0.0% | -6170.6% | -$89M | $25M | $186M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $21M | -$1M | 99.5% | -4.7% | — | $50M | $38M |
| Dec '25 | $5M | -$16M | 96.3% | -269.1% | -$17M | $54M | $34M |
| Sep '25 | $14M | -$13M | 99.9% | -85.9% | -$24M | $57M | $50M |
| Jun '25 | $29M | $3M | 99.9% | 12.9% | — | $56M | $21M |
| Mar '25 | $1M | -$25M | 97.6% | -2034.8% | — | $101M | $63M |
| Dec '24 | $27M | -$34M | 98.7% | -123.3% | -$22M | $100M | $67M |
| Sep '24 | $2M | -$65M | 95.9% | -3639.6% | -$54M | $100M | $35M |
| Jun '24 | $2M | -$53M | 89.9% | -3360.9% | -$49M | $99M | $36M |
| Mar '24 | $1M | -$48M | 97.3% | -4011.8% | -$55M | $100M | $96M |
| Dec '23 | $702000 | -$50M | 90.0% | -6657.7% | -$51M | $100M | $22M |
| Sep '23 | $162000 | -$51M | 95.7% | -30636.4% | -$42M | $99M | $21M |
| Jun '23 | $317000 | -$45M | 97.5% | -13955.8% | -$38M | $99M | $102M |
| Mar '23 | $24000 | -$32M | 100.0% | -129758.3% | -$32M | $49M | $26M |
| Dec '22 | $28000 | -$30M | 100.0% | -108135.7% | -$23M | $49M | $46M |
| Sep '22 | $39000 | -$23M | 100.0% | -59217.9% | -$19M | $24M | $19M |
| Jun '22 | $35000 | -$25M | 100.0% | -68591.4% | -$24M | $24M | $21M |
| Mar '22 | — | -$23M | — | — | -$23M | $24M | $60M |
| Sep '21 | $23000 | -$23M | 100.0% | -99834.8% | -$17M | — | $92M |
| Jun '21 | $234000 | -$18M | 100.0% | -7674.8% | -$23M | — | $90M |
| Mar '21 | $27000 | -$21M | 100.0% | -77181.5% | -$25M | — | $98M |
How the market has priced LXRX against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Lexicon Pharmaceuticals, Inc.'s revenue has grown 15.7% per year. These are computed facts, not advice.
As of FY2025, Lexicon Pharmaceuticals, Inc. reported $54M of total debt against $34M of cash.
In FY2025, gross margin was 99.4%, operating margin -98.2%, and net margin -101.1%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.